Eli Lilly disclosed that its Phase 3 VIVID‑2 study of Omvoh (mirikizumab‑mrkz) produced 152‑week data showing 92.4 % of patients achieved clinical remission and 91.2 % achieved steroid‑free remission. The results were presented at the 21st Congress of the European Crohn’s and Colitis Organisation in Stockholm, which ran from February 18‑21, 2026, and the company announced the findings on February 19, 2026.
The durability of Omvoh’s effect is unique among IL‑23p19 inhibitors. The monthly dosing schedule and sustained remission rates over three years give the drug a competitive edge over rivals such as Skyrizi, Tremfya, and Stelara, and position Lilly to expand its share of the growing global Crohn’s disease market, projected to reach $13.8 billion in eight major markets by 2032.
"Too many people with inflammatory bowel disease never achieve lasting remission, leaving them vulnerable to cumulative damage from poorly controlled inflammation that can result in emergency hospitalizations or surgery. Omvoh is redefining what durable disease control can look like, with long‑term data showing patients treated with Omvoh stayed in remission and experienced fewer serious complications over three years, underscoring its potential to alter the course of the disease," said Adrienne Brown, Executive Vice President and President of Lilly Immunology.
The data follow Omvoh’s 2023 FDA approval for ulcerative colitis and its 2025 approval for Crohn’s disease, and they reinforce the drug’s clinical value in a field where only a handful of biologics compete for market share. The low rates of hospitalization and surgery reported in the study suggest that Omvoh could reduce long‑term health‑care costs, a factor that may accelerate payer coverage and adoption by clinicians.
Eli Lilly’s leadership views the long‑term results as a catalyst for continued investment in the Omvoh pipeline and a strengthening of its competitive stance in the IBD market. The evidence base now supports broader regulatory submissions, more favorable payer negotiations, and a potential increase in revenue from a drug that can deliver sustained remission with a convenient monthly regimen.
"Seeing more than 90% of patients maintain steroid‑free remission through three years on consistent monthly dosing, with 80% also experiencing relief from the disruptive symptoms of bowel urgency, gives providers confidence in Omvoh for outcomes that can last," added Edward Barnes, Associate Professor of Medicine at the University of North Carolina at Chapel Hill.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.